Thomas L. Rodgers, an Executive Vice President and Chief Strategy & BDO at McKesson Corp (NASDAQ:MCK), recently sold common stock valued at $604,420, according to a filing with the Securities and Exchange Commission (SEC) Form 4.
These transactions spanned two days in June 2026, specifically on June 1 and June 2. The total sale involved 822 shares of common stock, which were disposed of at prices ranging from $735.27 to $735.5 per share.
The disposition was executed through a pre-arranged Rule 10b5-1(c) plan that Mr. Rodgers had initially adopted on August 18, 2025. On June 1, the sale comprised 123 shares at $735.5 per share. The subsequent day, June 2, saw the sale of an additional 699 shares priced at $735.27 per share.
Following these recent transactions, Mr. Rodgers currently holds a direct ownership stake of 2,268 shares of McKesson common stock.
The insider selling activity takes place while McKesson is trading at $735.51 and maintaining a market capitalization of $88.44 billion. From an analytical perspective, certain third-party assessments suggest the company's valuation may be attractive. Specifically, InvestingPro analysis indicates that the stock appears undervalued relative to its Fair Value, potentially placing it among opportunities listed as 'Most Undervalued'.
Furthermore, the financial metrics suggest favorable positioning: McKesson trades with a Price-to-Earnings (P/E) ratio of 19.09 and exhibits a notably low Price/Book Earnings Graph (PEG) ratio of 0.38. These figures point toward an attractive valuation when compared against projected growth prospects.
Q4 2026 Performance and Strategic Developments
In separate corporate news, McKesson Corporation released its fourth-quarter earnings report for fiscal year 2026. The financial results presented a mixed picture of performance across various operational areas.
On the positive side, the company surpassed market expectations regarding profitability. McKesson reported an actual Earnings Per Share (EPS) of $11.69, which exceeded the analyst forecast of $11.57. However, this strong earnings figure was offset by a decline in top-line revenue. The corporation's total revenue reached $92.3 billion, falling below the anticipated revenue target of $101.23 billion.
In terms of strategic maneuvering, McKesson also announced a significant investment deal pertaining to its Medical-Surgical Solutions business unit. Apollo-managed funds participated in this transaction, investing $1.25 billion into convertible preferred equity. This investment secured approximately a 13% interest stake in the unit, thereby valuing the entire Medical-Surgical Solutions business at an estimated $13 billion.
Market Context and Analysis
The combination of executive stock sales, mixed quarterly financial results, and large-scale strategic investments paints a multifaceted picture of McKesson’s current market standing. The company's valuation metrics, such as the low PEG ratio of 0.38 and P/E ratio of 19.09, suggest that many analysts view the stock favorably from a relative valuation standpoint.
These recent developments highlight both underlying financial challenges, specifically evidenced by the revenue shortfall in Q4 2026, and active strategic commitments, such as the $1.25 billion investment into Medical-Surgical Solutions. The overall picture suggests that while operational revenues faced headwinds, the company is simultaneously pursuing major capital injections to bolster key business segments.